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ABSTRACT   Concurrent chemoradiotherapy (CRT) is the recommended treatment for 
localized extranodal natural killer/T-cell lymphoma, nasal type (ENKL). In 2009, the Japan 
Clinical Oncology Group first documented the safety and efficacy of a regimen involving 
radiotherapy (RT) plus dexamethasone, etoposide, ifosfamide, and carboplatin (DeVIC) in their 
phase I/II trials (JCOG0211 study). The application of this regimen has drastically improved 
outcomes of patients with localized ENKL. In 2013, the current guidelines were made to the 
cost in JCOG0211 study. 
   We retrospectively investigated the outcomes of three patients who received CRT for stage 
localized ENKL at the Kawasaki Medical School Hospital between August 2007 and March 
2011. Our CRT protocol differed from that used in the JCOG0211 study as we used a different 
shrinking field RT method. A recent report on shrinking or extended-field RT raised questions 
regarding which fields are appropriate. Thus, we compared our clinical results with those 
of the JCOG0211 study and analyzed the effect of the differences in field size on clinical 
results. The median follow-up of the three patients in the present study was 9 months (range, 
5-106 months), two and one of whom achieved complete and partial responses, respectively. 
Regarding adverse events, no severe acute side effects (e.g., mucositis) higher than Grade 4 
were observed. 
   We reviewed cases and the JCOG0211 study which we experienced in the past about fields 
of the RT. The present study described our experiences with three patients receiving shrinking 
field RT. doi：10.11482/KMJ-E202046017　(Accepted on December 25, 2019)
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Modified radiation fields in RT for treating ENKL
   The extent of the clinical target volume (CTV) 
and the optimal dose in RT remain controversial for 
patients with localized ENKL９）. Several studies 
defined an extended CTV encompassing the entire 
nasal cavity, nasopharynx, bilateral paranasal cavity, 
and gross tumor volume (GTV)６，７， 15）, while others 
defined a smaller target volume９－14）. Recent novel 
chemoradiotherapy regimens have achieved 2-year 
overall survival (OS) rates of 76-89%６，７，10，15－17）; 
therefore, concerns regarding late radiation toxicities 
and the quality of survivorship are increasing. 
Because localized ENKL is generally located in 
the nasal cavity, the exposure of the optic pathway 
and eyes to radiation is problematic in many long-
term survivors. Yamaguchi et al.６，７） reported the 
outcomes of 33 patients with stage I/IIE ENKL who 
were administered three cycles of 2/3DeVIC and 
extended-field RT. The 5-year OS rate was 73%, 
and local recurrence occurred in two patients (6.1%). 
However, 11 patients (33%) developed Grade 1 
or 2 toxicities in the eye. In the present study, we 
treated patients having localized ENKL with the 
full-DeVIC regimen and a modified RT protocol. 
To avoid toxicities to normal tissue, we employed 
a smaller target volume than that used in previous 
DeVIC studies６，７，15）. This study described our 
experiences with the use of full-DeVIC combined 
with shrinking field RT for treating localized ENKL.
   In this study, all patients were irradiated with 
a 4-6-MV photon beam. One patient was treated 
using X-ray simulation RT and two were treated 
with three-dimensional conformal RT (3D-CRT) 
(Fig. 1, Table 1). The prescribed radiation doses 
ranged from 50 to 60 Gy in daily fractions of 1.8-
2.0 Gy. A mouth spacer and a two-step cone down 
technique were used to reduce local radiation 
toxicity. The first-step RT covered the tumor plus 
a prophylactic volume (Fig. 2). We defined first-
step RT as “shrinking field RT.” The shrinking field 
comprised the radiation field of the prophylactic 
INTRODUCTION
   Localized extranodal natural killer/T-cell 
lymphoma, nasal type (ENKL) is a rare type of 
lymphoma with a relatively high prevalence in 
East Asia１－３）. Based on the results of studies 
conducted in the 1990s３）, approximately 70–90% 
of ENKL cases involved localized disease４） with a 
poor response to cyclophosphamide, doxorubicin, 
vincristine, and prednisone chemotherapy. Although 
the transient remission of localized ENKL has 
been observed, with a complete response (CR) 
rate of 65%, the rate of recurrence is high with 
radiotherapy (RT) alone; consequently, poor 
prognosis is observed for long-term survival５）. 
More recently, concurrent chemoradiotherapy (CRT) 
based on a dexamethasone, etoposide, ifosfamide, 
and carboplatin regimen (a two-third dose of DeVIC 
[2/3DeVIC]) has been recommended for treating 
localized ENKL in Japan, which has increased the 
5-year overall survival rate by 70%６，７）. The Japan 
Clinical Oncology Group (JCOG) 0211 study by 
Yamaguchi et al.６－８） was the first to evaluate the 
clinical response of concurrent CRT using DeVIC. 
In 2013, RT plus 2/3DeVIC therapy became the 
standard treatment for localized ENKL in Japan. 
However, a recent report of shrinking field９－14） or 
extended-field６，７，14） RT has raised debate regarding 
which fields are appropriate.
   The Kawasaki Medical School Hospital uses 
treatment protocols that differ in chemotherapy and 
RT fields from those described in the JCOG0211 
study. This study retrospectively compared the 
clinical outcomes of patients who received CRT 
for localized ENKL at our hospital before the 
introduction of RT plus 2/3DeVIC therapy with 
those of patients who participated in the JCOG0211 
study to analyze the effects of the differences in 
radiation field size on clinical results. This study 
assessed the efficiency of full-DeVIC combined 
with shrinking field RT in treating localized ENKL.
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area, including the CTV, nasal cavity, nasopharynx, 
and ipsilateral paranasal sinuses (Fig. 2). All patients 
received additional radiation to the tumor area after 
completing first-step RT. For additional radiation 
to the tumor area, the CTV was defined as the GTV 
plus margins of 0.7-1.0 cm within the ipsilateral 
nasal cavity, paranasal cavities, and nasopharynx 
(Fig. 2). The planning target volume comprised the 
CTV plus a 0.5-cm margin (Fig. 2).
Cases treated with the modified radiation field
   This retrospective study was approved by the 
Institutional Board of our university (number 
2788). Informed consent was obtained from all 
patients before treatment. Between August 2007 
and March 2011, three patients with localized 
ENKL were administered RT in our hospital. 
Their ages ranged from 27  to 49  years, and 
their performance status ranged from 0 to 2. 
All diagnoses were pathologically confirmed as 
ENKL based on the morphological criteria of the 
World Health Organization classification１，18－21）. 
Immunohistochemical analysis confirmed positive 
CD56 expression and negative CD20 expression 
in localized ENKL cells. Fluorescence in situ 
hybridization for Epstein–Barr virus (EBV)-
encoded early small RNA (EBER) was performed 
to determine the EBV infection status. At the time 
Fig. 1. 【legend】LINAC-graphy (left) and 3-dimensional conformal radiotherapy (right) showing dose distribution in case 2 of 
localized nasal extranodal natural killer/T-cell lymphoma.
Table 1. Summary of treatment and outcomes in our cases (n=3)   











period (months, time 






1 X-ray simulation (50 Gy)
full-DeVIC×2
 (Precedent 




Stomach (1 m), 
Liver, Spleen  (3 m)
5 Grade 1 mucositis and Grade 1 dermatitis
2 3D-CRT (50 Gy)
full-DeVIC×3
(Precedent 
combination of the 
radiotherapy)
CR No No 106 Grade 1-2 mucositis and Grade 1 dermatitis
3 3D-CRT (60 Gy) full-DeVIC×4(concurrent)  CR No Liver (5 m) 9
 Grade 2-3 mucositis 
and Grade 1-2 
dermatitis
Abbreviations: 3D-CRT; 3-dimensional conformal radiotherapy, DeVIC, dexamethasone, etoposide, ifosfamide, and carboplatin; RT, 
radiotherapy; PET, positron emission tomography; CR, complete response; PR, partial response
Figure 1.
(left, LINAC-graphy)                                     (right, 3-dimensional conformal radiotherapy) 
Figure 1.
(left, LINAC-graphy)                                     (right, 3-dimensional conformal radiotherapy) 
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of diagnosis, computed tomography and magnetic 
resonance imaging of the involved sites and bone 
marrow biopsy were performed for staging, when 
possible. 18F-fludeoxyglucose positron emission 
tomography was performed since 2007. Staging 
was performed based on the Ann Arbor staging 
system１－３）. Patients with contiguous involvement 
extending to adjacent tissues or organs were 
defined as having stage IE disease. The Eastern 
Cooperative Oncology Group performance status, 
physical examinations, systemic B symptoms, 
complete blood count, biochemical profiles, and 
serum lactate dehydrogenase levels were evaluated. 
Evaluation of International Prognostic Index and 
NK/T-cell lymphoma Prognostic Index22，23） showed 
good prognostic factors (International Prognostic 
Index score: low; Natural Killer/T-cell Lymphoma 
Prognostic Index23）: Group 1-2) for all patients. 
We showed results in Table 2. The CRT regimens 
administered to our patients are summarized in 
Table 1. All patients received the full-DeVIC 
regimen (40 mg/d dexamethasone intravenously on 
Fig. 2. 【legend】Comparison between the radiation field with our two-step cone down technique (shrinking field) and the 
radiation field in the JCOG0211 study (left).
Our two-step cone down technique (shrinking field) and the JCOG0211 study of the radiation field showing plans for one patient 
with localized nasal extranodal natural killer/T-cell lymphoma (right).
Schema is shown, ① Our hospital (red) : First-step RT covered the tumor plus a prophylactic volume (shrinking field), ② Our 
hospital (white) : Additional radiation to the tumor area, ③ JCOG0211 (blue) :  PTV.
【Abbreviations】RT, radiotherapy; GTV, gross tumor volume; CTV, clinical target volume; PTV, planning target volume
Table 2. Clinical characteristics (n=3)














1 27 Male IE Low Group 2 －




involvement CD20 – , CD56  ＋ ＋
2 49 Male IE Low Group 1 － One side of nasal cavity
Not  
involvement
CD20 –, CD56 +, TIA-1+, 
CD30+/-, CD3ε＋ ＋
3 35 Male IE Low Group 1 － One side of nasal cavity
Not  
involvement CD20 –, CD56 + ＋
Abbreviations: IPI, International Prognostic Index; Int., Intermediate; NK-PI, natural killer/T-cell lymphoma prognostic index23）CT and 
MRI, computed tomography and magnetic resonance imaging; PET/CT, 18F-fludeoxyglucose positron emission tomography;  EBER, 
Epstein-Barr virus-encoded small RNA
 esod TR dleif TR
(Gy/fracion)
CTV: GTV with a margin = 0.7-1.0 cm + the ipsilateral nasal cavity 
and ipsilateral paranasal sinuses. 
PTV : CTV with a 0.5-cm margin.
Stage E
50-60 /25-30
CTV : GTV with a margin > 2.0 cm + the entire nasal cavity and 
bilateral parasinuses.
PTV : CTV with a 0.5-cm margin
Note: For stage E disease, PTV included the area of the involved
cervical lymph node.
Stage E 50 / 25
Stage E 50.4 / 28
Schema:
Our hospital (red) : First-step RT 
covered the tumor plus a prophylactic 
volume (shrinking field).  
Our hospital (white) : Additional 
radiation to the tumor area.




Abbreviations: RT, radiotherapy; GTV, gross tumor volume; 
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days 1-3, 100 mg/m2 etoposide intravenously over 
2 h on days 1-3; 1.5 g/m2 ifosfamide intravenously 
over 3 h on days 1-3; and 300 mg/m2 carboplatin 
intravenously over 30 min on day 1). Patients 
with localized ENKL were considered candidates 
for radical RT. Only case 3 were administered 
concurrent CRT regimens. 
   After RT, the patients were followed up and 
evaluated at 1- to 3-month intervals. Local 
recurrence was pathologically confirmed. The 
patients underwent 18F-fludeoxyglucose positron 
emission tomography-computed tomography and 
magnetic resonance imaging (MRI) to evaluate 
treatment response. The tumor responses were 
Fig. 4. 【legend】Case 2 was administered combination of precedent RT (50Gy) to the nasal cavity and autologous peripheral 
blood stem cell transplantation after full-DeVIC. We showed PET/CT of each timing of orthodontic treatment.
【Abbreviations】RT, radiotherapy; fr, fraction; DeVIC, dexamethasone, etoposide, ifosfamide, and carboplatin; Auto-PBSCT, 
autologous peripheral blood stem cell transplantation; CR, complete response; PET/CT, 18F-fludeoxyglucose positron emission 
tomography
Fig. 3. 【legend】Case2, contrast magnetic resonance imaging (left: axial, right: 
coronal) of paranasal sinuses demonstrating tumor: An 30 × 14 × 21mm size (white 









two-step cone down technique





Abbreviations: RT, radiotherapy; fr, fraction; DeVIC, dexamethasone, etoposide, ifosfamide, and carboplatin; Auto-PBSCT, 
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assessed according to Cheson’s criteria20）. Toxicities 
were evaluated using the Common Torminology 
Criteria for Adverse Events, version 4.021）. 
<Case 1>
   Case 1 was administered precedent combination 
of RT (50Gy) to the nasal cavity and achieved local 
control with partial response but developed stomach, 
liver, and spleen invasion at 1-3 months after RT 
and died 5 months after RT. The patient’s outcomes 
are summarized in Table 1.
<Case 2>
   Although not recommended in the latest guidelines 
from the Japanese Society of Hematology24）, this 
patient underwent autologous peripheral blood 
stem cell transplantation after full-DeVIC. With 
or without association with the transplant, there 
was not a recurrence during 106 months. Case 2 
experienced acute Grade 1-2 mucositis and Grade 
1 dermatitis but did not experience late toxicity. We 
showed MRI and clinical course of case 2 to Fig. 3 
and 4.
<Case 3>
   The survival period of Case 3 was 9 months. 
Despite achieving CR, this case experienced liver 
invasion in the fifth month after concurrent CRT. 
Regarding safety, the patient experienced acute 
Grade 2-3 mucositis and Grade 1-2 dermatitis 
associated with concurrent CRT. The patient 
received full-DeVIC and four courses of RT in 
another hospital, and it becomes the changing 
hospital in this hospital, and the fact is unknown 
subsequently. However, it is a case of 2007 before 
the guidelines induction, and reasons include that 
the therapies in each institution were not unified 
when full-DeVIC guesses a reason performed 
four courses in. However, shrinking field RT 
administered by the other hospital was similar to 
that administered in our institution.
DISCUSSION
   We showed treatment eras among patients with 
newly diagnosed ENKL treated in Japan (Fig. 5). In 
the past, radiotherapy alone has been chosen. Also, 
there were the treatment eras when radiotherapy 
preceded before chemotherapy and was performed. 
Fig. 5. 【legend】 The RT and/or chemotherapy according to treatment eras among patients with newly diagnosed ENKL treated 
in clinical practice. The different rates of overall survival (OS) in individual eras, 40 to 42% of 5y OS５，25） until 2006, 87% of 8y 
OS26，27） during 200 to 2009, and 70% of 5y OS７） since 2009 are schematically shown. 
【Abbreviations】 OS, overall survival; DeVIC, dexamethasone, etoposide, ifosfamide, and carboplatin; RT, radiotherapy; CHOP, 
cyclophosphamide, doxorubicin, vincristine, and prednisone
Figure 5.
〜2006 : RT (50-60Gy)  alone or CHOP etc.
2000〜2009 : RT (50-54Gy) followed by  
combination chemotherapy (CHOP etc. or full-DeVIC)
2009〜 : concurrent RT   
(50-50.4Gy) + 2/3DeVIC 
in Japan
5y OS:   






extended-field RT or shrinking field RT 
Abbreviations: OS, overall survival; DeVIC, dexamethasone, etoposide, ifosfamide, and carboplatin; RT, radiotherapy; CHOP, cyclophosphamide, 
doxorubicin, vincristine, and prednisone 
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However, they consisted of the collection of the low 
report of the evidence level.
   In 2013, the combination of 2/3DeVIC therapy 
and RT became the standard treatment for localized 
ENKL in Japan, which dramatically increased 
the average patient survival time. The reasons for 
using shrinking field RT in our institution included 
avoiding RT-associated adverse events when treating 
localized ENKL and increasing survival. The 
localized fields used at our institution were smaller 
than those used in the JCOG0211 study. Based 
on the three cases described in this review, it was 
difficult to evaluate the effects of shrinking field RT 
because we could evaluate only three patients, two 
of whom died because of distant metastases within 
1 year. Moreover, the one case with long-term 
survival underwent stem cell transplantation, which 
was not recommended in the 2018 guidelines24）. 
Clinical evaluation of shrinking field RT is currently 
not possible.
   Increased numbers of cases are required; however, 
this is difficult to achieve owing to the low 
incidence rate of this disease in single institutions.
   In contrast, it may be necessary to think about 
making a proposal for JCOG, and switching from 
present JCOG0211 toward shrinking field RT for 
localized ENKL in institution and others. Because it 
is difficult to distinguish between normal tissue (e.g., 
eyes, central nervous system, mucosa) and organs 
in the head and neck owing to their complicated 
structures, these targets are often treated using 
extended-field RT. However, extended-field RT 
increases the risk of adverse events and reduces a 
patient’s quality of life. Thus, we applied shrinking 
field RT to prevent negative effects on a patient’s 
quality of life.
   Second, adverse events (mucositis, optic neuritis, 
myelosuppression)  may develop fol lowing 
concurrent CRT for treating localized ENKL. 
Thus, shrinking field RT was applied to reduce the 
occurrence of these adverse events. To avoid normal 
tissue toxicities, we utilized a smaller shrinking 
field than that used in the JCOG0211 study (Fig. 
2). In the JCOG0211 study, one patient developed 
RT-associated Grade 4 dermatitis (paranasal skin 
necrosis and perforation)８）. The shrinking field RT 
used in our institution could potentially avoid the 
development of Grade 4 acute radiation toxicity. 
   However, as the present study included only three 
cases, it was difficult to prove this effect. As for the 
future prospects, number of cases aims for it being 
to 10 in a shrinking field RT that we introduced this 
time. 
CONCLUSION
   We evaluated the effects of using a modified 
shrinking field RT regimen in CRT for treating 
localized ENKL. The localized fields used at our 
institution were smaller than those specified in 
the JCOG0211 protocol. We observed good local 
control for this shrinking field RT regimen for 
localized ENKL. Furthermore, no serious toxicity 
was observed. Now still, a report of shrinking 
field or extended-field RT is accomplished, and 
a debate to decide which fields are appropriate is 
not accompanied by the end. This study described 
our experiences with a regimen comprising DeVIC 
combined with shrinking field RT for treating 
localized ENKL.
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